|
1
|
Forman D, de Martel C, Lacey CJ,
Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J,
Bray F, Plummer M and Franceschi S: Global burden of human
papillomavirus and related diseases. Vaccine. 30(Suppl 5): F12–F23.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
World Health Organization, . Cervix Cancer
ScreeningIARC Handbook of Cancer Prevention. 1st. 10. IARC Press;
Lyon: 2005, pp. 168–173
|
|
4
|
Muñoz N, Castellsagué X, de González AB
and Gissmann L: Chapter 1: HPV in the etiology of human cancer.
Vaccine. 24(Suppl 3): 1–10. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Walboomers JM, Jacobs MV, Manos MM, Bosch
FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N:
Human papillomavirus is a necessary cause of invasive cervical
cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burd EM: Human papillomavirus and cervical
cancer. Clin Microbiol Rev. 16:1–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arends MJ, Buckley CH and Wells M:
Aetiology, pathogenesis, and pathology of cervical neoplasia. J
Clin Pathol. 51:96–103. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Richart RM: A modified terminology for
cervical intraepithelial neoplasia. Obstet Gynecol. 75:131–133.
1990.PubMed/NCBI
|
|
9
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Surviladze Z, Sterk RT, DeHaro SA and
Ozbun MA: Cellular entry of human papillomavirus type 16 involves
activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway
and inhibition of autophagy. J Virol. 87:2508–2517. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gulhati P, Cai Q, Li J, Liu J, Rychahou
PG, Qiu S, Lee EY, Silva SR, Bowen KA, Gao T and Evers BM: Targeted
inhibition of mammalian target of rapamycin signaling inhibits
tumorigenesis of colorectal cancer. Clin Cancer Res. 15:7207–7216.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Clark C, Shah S, Herman-Ferdinandez L,
Ekshyyan O, Abreo F, Rong X, McLarty J, Lurie A, Milligan EJ and
Nathan CO: Teasing out the best molecular marker in the AKT/mTOR
pathway in head and neck squamous cell cancer patients.
Laryngoscope. 120:1159–1165. 2010.PubMed/NCBI
|
|
13
|
Molinolo AA, Marsh C, El Dinali M, Gangane
N, Jennison K, Hewitt S, Patel V, Seiwert TY and Gutkind JS: mTOR
as a molecular target in HPV-associated oral and cervical squamous
carcinomas. Clin Cancer Res. 18:2558–2568. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Coleman LJ, Peter MB, Teall TJ, Brannan
RA, Hanby AM, Honarpisheh H, Shaaban AM, Smith L, Speirs V,
Verghese ET, et al: Combined analysis of eIF4E and 4E-binding
protein expression predicts breast cancer survival and estimates
eIF4E activity. Br J Cancer. 100:1393–1399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
No JH, Jeon YT, Park IA, Kim YB, Kim JW,
Park NH, Kang SB, Han JY, Lim JM and Song YS: Activation of mTOR
signaling pathway associated with adverse prognostic factors of
epithelial ovarian cancer. Gynecol Oncol. 121:8–12. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inamdar KV, Romaguera JE, Drakos E,
Knoblock RJ, Garcia M, Leventaki V, Medeiros LJ and Rassidakis GZ:
Expression of eukaryotic initiation factor 4E predicts clinical
outcome in patients with mantle cell lymphoma treated with
hyper-CVAD and rituximab, alternating with rituximab, high-dose
methotrexate, and cytarabine. Cancer. 115:4727–4736. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kouvaraki MA, Liakou C, Paraschi A, Dimas
K, Patsouris E, Tseleni-Balafouta S, Rassidakis GZ and Moraitis D:
Activation of mTOR signaling in medullary and aggressive papillary
thyroid carcinomas. Surgery. 150:1258–1265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sotlar K, Diemer D, Dethleffs A, Hack Y,
Stubner A, Vollmer N, Menton S, Menton M, Dietz K, Wallwiener D, et
al: Detection and typing of human papillomavirus by e6 nested
multiplex PCR. J Clin Microbiol. 42:3176–3184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vega F, Medeiros LJ, Leventaki V, Atwell
C, Cho-Vega JH, Tian L, Claret FX and Rassidakis GZ: Activation of
mammalian target of rapamycin signaling pathway contributes to
tumor cell survival in anaplastic lymphoma kinase-positive
anaplastic large cell lymphoma. Cancer Res. 66:6589–6597. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spangle JM and Münger K: The human
papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling
and increases protein synthesis. J Virol. 84:9398–9407. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feng W, Duan X, Liu J, Xiao J and Brown
RE: Morphoproteomic evidence of constitutively activated and
overexpressed mTOR pathway in cervical squamous carcinoma and high
grade squamous intraepithelial lesions. Int J Clin Exp Pathol.
2:249–260. 2009.PubMed/NCBI
|
|
22
|
Faried LS, Faried A, Kanuma T, Sano T,
Nakazato T, Tamura T, Kuwano H and Minegishi T: Predictive and
prognostic role of activated mammalian target of rapamycin in
cervical cancer treated with cisplatin-based neoadjuvant
chemotherapy. Oncol Rep. 16:57–63. 2006.PubMed/NCBI
|
|
23
|
Matthews-Greer J, Caldito G, de Benedetti
A, Herrera GA, Dominguez-Malagon H, Chanona-Vilchis J and
Turbat-Herrera EA: eIF4E as a marker for cervical neoplasia. Appl
Immunohistochem Mol Morphol. 13:367–370. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Neshat MS, Mellinghoff IK, Tran C, Stiles
B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H and Sawyers CL:
Enhanced sensitivity of PTEN-deficient tumors to inhibition of
FRAP/mTOR. Proc Natl Acad Sci USA. 98:10314–10319. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Podsypanina K, Lee RT, Politis C, Hennessy
I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, et al: An
inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase
activity in Pten+/-mice. Proc Natl Acad Sci USA. 98:10320–10325.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ronco G, Biggeri A, Confortini M, Naldoni
C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, et
al: Health technology assessment report: HPV DNA based primary
screening for cervical cancer precursors. Epidemiol Prev. 36(3-4):
Suppl 1. e1–e72. 2012.
|
|
28
|
Arbyn M, Ronco G, Anttila A, Meijer CJ,
Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R
and Peto J: Evidence regarding human papillomavirus testing in
secondary prevention of cervical cancer. Vaccine. 30(Suppl 5):
F88–F99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oh KJ, Kalinina A, Park NH and Bagchi S:
Deregulation of eIF4E: 4E-BP1 in differentiated human
papillomavirus-containing cells leads to high levels of expression
of the E7 oncoprotein. J Virol. 80:7079–7088. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang S, Pang T, Gao M, Kang H, Ding W, Sun
X, Zhao Y, Zhu W, Tang X, Yao Y and Hu X: HPV E6 induces eIF4E
transcription to promote the proliferation and migration of
cervical cancer. FEBS Lett. 587:690–697. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Won HS, Jung CK, Chun SH, Kang JH, Kim YS,
Sun DI and Kim MS: Difference in expression of EGFR, pAkt, and PTEN
between oropharyngeal and oral cavity squamous cell carcinoma. Oral
Oncol. 48:985–990. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aderhold C, Faber A, Umbreit C, Birk R,
Weiss C, Sommer JU, Hörmann K and Schultz JD: Targeting mTOR and
AREG with everolimus, sunitinib and sorafenib in HPV-positive
and-negative SCC. Anticancer Res. 35:1951–1959. 2015.PubMed/NCBI
|
|
33
|
Tinker AV, Ellard S, Welch S, Moens F,
Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA and MacKay H: Phase
II study of temsirolimus (CCI-779) in women with recurrent,
unresectable, locally advanced or metastatic carcinoma of the
cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND
199). Gynecol Oncol. 130:269–274. 2013. View Article : Google Scholar : PubMed/NCBI
|
